Developing innovative new ways to treat diseases in people and animals.

HylaPharm is a university spinout company developing cancer chemotherapies targeted for potentially deadly, locally advanced cancers that affect nearly 200,000 Americans each year. Unlike conventional chemotherapy that enters vein and diffuses all over the body before getting to the tumor, our patented drug HylaPlat™ is injected into tumor or surrounding at-risk tissues. This results in very high tumor dosing. HylaPlat™ then drains into local lymph nodes, which is where tumors generally metastasize first. Our technology makes treatment of certain types of cancer, including breast cancer and head and neck cancer, both safer and more effective in animal trials. HylaPlat™ has already shown efficacy in multiple mouse models, and in several pet dogs with large, naturally occurring cancers as well as multiple laboratory models. HylaPlat™ works by complexing conventional chemotherapy with nano-sized Hyaluronan, a natural compound in the body that cancers seek and bind.HylaPlat’s™ development path may be shorter because its initial target is an “orphan disease,” and because it is a novel complex of already approved drugs. The Kansas BioScience Authority has funded our upcoming FDA Investigational New Drug–enabling animal trials. Our team is based out of incubator space in Lawrence, Kansas.

11/28/2018: HylaPharm completes $750k Kansas Angel Credit raise.

6/8/2018: New treatment from KU Cancer Center, tested on dogs, could eliminate need for chemotherapy.

10/26/2017: HylaPharm completes $400k Kansas Angel Credit raise.

10/22/2017: HylaPharm is selected to represent the University of Kansas at the Science Coalition’s Sparking Economic Growth conference in Washington D.C.

1/13/2017: HylaPharm has received a second SBIR grant from the National Cancer Institute (division of National Institutes of Health) to develop aerosolized platinum nanoparticle chemotherapy for lung cancer.

1/6/2017: Pet dog with inoperable cancer is now cancer free.

10/1/2016: Hylapharm completed SBIR contract for the National Cancer Institute (division of National Institutes of Health) to develop NanoTor (hyaluronan rapamycin nano conjugates) for treatment of breast cancer. Phase II of this SBIR is pending.